LONDON (Reuters) - GlaxoSmithKline and its partner Theravance said on Friday they had submitted their new combination lung drug - to be known as Breo and Relvar - for regulatory approval in the United States and Europe.
via Reuters: Health News Read More Here..
No comments:
Post a Comment